Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE The presence of one of the three following CDKN2A alterations-p.(Ala148Thr) mutation, whole homozygous or heterozygous gene loss, or promotor methylation > 8%-was observed in 13 of the 17 relapsing meningiomas and was strongly associated with recurrence (p < 0.0001) and a Ki67 labeling index > 7% (p = 0.004). 31729637 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE The most frequently methylated genes in both types of meningiomas were p14ARF, RASSF1A, and p15INK4B. 25648363 2015
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Compared with MNG, MHPCs showed strong VIM (100% of cases), CD99 (62%), bcl-2 (87%), and p16 (75%) staining but only focal positivity with EMA (33%) and NSE (37%). 26514459 2015
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE In this study, we aimed at investing methylation of MGMT (DNA repair), CDKN2A (cell cycle control), GSTP1 (detoxification), and THBS1 (angiogenesis inhibitor) genes, which are known to be unmethylated in normal tissue, in meningioma samples. 22288845 2012
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE In addition to alterations of CDKN2A, p14(ARF), and CDKN2B tumor suppressor genes on 9p21, a contribution of the wingless (wnt) pathway with alterations of the E-cadherin and beta-catenin proteins, as well as alterations of the hedgehog signaling pathway have been implicated in anaplastic meningiomas. 20809251 2010
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease LHGDN The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. 18374497 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade. 17924978 2008
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Our findings suggest that Ki-ras and ERCC2 SNPs are possible markers for meningioma formation, whereas cyclin D1 and p16 SNPs may be markers of genes that have an inverse effect on the risk to develop meningioma in irradiated and nonirradiated populations. 15824172 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE To identify predictive markers of recurrence, a cohort of high-grade (24 World Health Organization [WHO] Grade II and six WHO Grade III) and low-grade (21 WHO Grade I) meningiomas was investigated for losses of heterozygosity (LOHs) on chromosomes 1p, 9p, 10q, 14q, and 22q, a deletion of CDKN2A, and telomerase activity. 15098535 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Accordingly, we examined the DNA methylation status of ten tumor-related genes (RB1, p16(INK4a), p73, MGMT, ER, DAPK, TIMP-3, p14(ARF), THBS1, and Caspase-8) in 98 meningiomas (68 grade I; 27 grade II; and 3 grade III samples) using methylation-specific PCR and sequencing. 15365725 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 PosttranslationalModification disease BEFREE In absence of p53 gene mutation, the high percentage of p14(ARF) gene methylation in high-grade meningioma may have been responsible for accumulation of wild-type p53 protein. 15073599 2004
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 Biomarker disease BEFREE Deletion of p16 or monosomy 9 was seen in 17% of benign, 52% of atypical, and 74% of anaplastic meningiomas (p < 0.001). 11958372 2002
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease LHGDN 14/39 (36%) benign and atypical but 5/7 (71%) anaplastic meningiomas contained no p14ARF mRNA.2/46 (4%) tumors failed to express pRB. 11859969 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE 14/39 (36%) benign and atypical but 5/7 (71%) anaplastic meningiomas contained no p14ARF mRNA.2/46 (4%) tumors failed to express pRB. 11859969 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE Two anaplastic meningiomas carried somatic point mutations in CDKN2A (c.262G>T: E88X and c.262G>A: E88K) and p14(ARF) (c.305G>T: G102V and c.305G>A: G102E). 11485924 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 AlteredExpression disease BEFREE The methylation status of the p16INK4A gene was not consistently associated with the expression of p16INK4A in meningiomas. 9824096 1998
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE We screened human primary and recurrent malignant glioma, juvenile pilocytic astrocytoma, medulloblastoma, and meningioma tissue specimens for alterations in p16 gene structure. 9049826 1997
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.100 GeneticVariation disease BEFREE In the present study, we evaluated a series of 31 dural HPCs (including 3 pairs of primary and recurrent tumor) and 26 meningiomas for alterations in the cell-cycle regulatory genes CDKN2/p16 and p53. 8834533 1996